We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new subcutaneous (SC) formulation for Biogen’s multiple sclerosis treatment Tysabri.
The issue whether a parliamentary panel report can be relied upon in judicial proceedings arose over alleged trials of the controversial HPV vaccine by some pharma companies